Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes
Agios provides update on Phase 2b trial of tebapivat in lower-risk myelodysplastic syndromes
Agios provides update on Phase 2b trial of tebapivat in lower-risk myelodysplastic syndromes
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.